Exhibit 10.2

CONFIDENTIAL TREATMENT REQUEST – EDITED COPY

 

 

*** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS
EXHIBIT.  CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***].  A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.

 

AMENDMENT NO. 1
TO
MANUFACTURING SERVICES AGREEMENT

THIS AMENDMENT NO. 1 TO MANUFACTURING SERVICES AGREEMENT (this “Amendment No.
1”) is made as of March 22, 2015, by and between SciClone Pharmaceuticals
International Ltd. (“Customer”); and Lonza Sales Ltd (“Lonza”).

WITNESSETH:

WHEREAS, Customer and Lonza are party to that certain Manufacturing Services
Agreement, dated as of April 30, 2014, (the “Agreement”); and

WHEREAS, the parties wish to amend the Agreement as more fully set forth herein;

NOW, THEREFORE, for and in consideration of the premises and the mutual
covenants and agreements contained herein and other good and valuable
consideration, the receipt, adequacy and sufficiency of which are hereby
acknowledged, the parties hereto hereby agree as follows:

1. Capitalized terms used in this Amendment No. 1 and not otherwise defined
herein shall have the respective meanings set forth in the Agreement.

2. The Agreement is hereby amended to add Appendix A attached hereto as Project
Plan SL-001 under the Agreement, effective as of the date first above
written.  Project Plan SL-001 supersedes any previous Project Plan under the
Agreement relating to the services described in Project Plan SL-001.

3. The Agreement is hereby amended to add Appendix C attached hereto, effective
as of the date first above written.  The attached Appendix C supersedes any
previous version of Appendix C.

4. Except as expressly set forth in this Amendment No. 1, the terms and
conditions of the Agreement shall remain in full force and effect.

IN WITNESS WHEREOF, each of the parties hereto has executed, or has caused its
duly authorized officer to execute, this Amendment No. 1 as of the date first
above written.

﻿

 

SciClone Pharmaceuticals International Ltd.

Lonza Sales Ltd

By: /s/ Friedhelm Blobel

By: /s/ Marie Leblanc

Name: Friedhelm Blobel

Name: Marie Leblanc

Title: Director

Title: Associate Director Key Account Management

﻿

By: /s/ Nadia Ziegler

﻿

Name: Nadia Ziegler

﻿

Title: Senior Legal Counsel

--------------------------------------------------------------------------------

 

 

*** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS
EXHIBIT.  CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***].  A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.

 

Appendix A

PROJECT PLAN SL-001

﻿

[***]

﻿

 

--------------------------------------------------------------------------------

 

 

*** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS
EXHIBIT.  CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***].  A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.

 

Appendix C

SPECIFICATIONS

﻿

[***]

﻿

 

--------------------------------------------------------------------------------